Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study

NCT06714370 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Central Nervous System Lymphoma (PCNSL)

Sponsor

Ono Pharmaceutical Co., Ltd.